First Databank, Inc.

FDB (First Databank) is a leading provider of drug and medical device databases and clinical decision support solutions, dedicated to helping healthcare professionals make precise medication decisions. The company's mission is to improve patient safety, operational efficiency, and healthcare outcomes by transforming complex drug knowledge into actionable, targeted, and effective solutions. Headquartered in South San Francisco, California, FDB also maintains offices in Indianapolis, Indiana, Exeter, England, Dubai, UAE, and Hyderabad, India.

FDB's core offerings include FDB MedKnowledge, a widely utilized source of drug information in the U.S. and Canada that provides comprehensive clinical data, pricing, and decision support for drug-drug interactions, allergies, and more. Other key products include FDB OrderKnowledge, a drug ordering knowledge base for physicians, and FDB Vela, a cloud-native ePrescribing network designed to streamline prescription information flow and provide real-time benefits verification. Additionally, FDB offers medical device databases to enhance clinical and operational outcomes, and Meducation, which simplifies medication instructions for patients in multiple languages.

In recent developments, FDB appointed David Delaney, MD, as its new President in February 2026, signaling a continued focus on AI-enabled, patient-specific medication intelligence. The company has been actively advancing its FDB MedProof MCP™ Server, an AI integration layer for clinical decision support and workflow automation, with recent announcements in March 2026 regarding its role in agentic integrations. FDB also expanded its FDB Vela network in April 2026 through a collaboration with Photon to enhance cost transparency and patient choice in ePrescribing, and launched RxWallet® on FDB Vela to provide real-time prescription price transparency for consumers.

Latest updates

FDB Bolsters IV Medication Safety with Gravimetric Data Module

Event summary

  • FDB launched a new Gravimetric Drug Density Module for its MedKnowledge platform on April 30, 2026.
  • The module provides NDC-level drug density data to improve accuracy in IV medication compounding, particularly for high-risk oncology therapies.
  • A peer-reviewed study found gravimetric verification increased detection of compounding errors by nearly 90-fold compared to traditional methods.
  • The module is initially focused on injectable antineoplastic medications, with plans for broader coverage.

The big picture

The launch of FDB’s gravimetric module reflects a growing trend towards automation and enhanced safety protocols in sterile compounding pharmacies, driven by rising drug costs and increasing regulatory scrutiny. This move positions FDB to capitalize on the demand for more precise medication decision support, particularly as healthcare organizations seek to optimize pharmacy operations and address workforce challenges. The module's availability as a standalone data solution suggests a broader strategy to serve technology partners and expand market reach beyond FDB's core MedKnowledge platform.

What we're watching

Adoption Rate
The speed at which health systems integrate the gravimetric module will depend on existing pharmacy IT infrastructure and the willingness to invest in new workflows, potentially creating a barrier to widespread adoption.
Content Expansion
FDB’s ability to expand the module’s coverage beyond injectable antineoplastic medications will be crucial for broader market appeal and demonstrate the scalability of their data curation efforts.
Competitive Response
Other drug knowledge providers may accelerate their own development of similar gravimetric verification solutions, intensifying competition in the clinical decision support market.

FDB Leverages AI to Automate ePrescribing, Reducing Pharmacy Workload

Event summary

  • FDB is presenting at the NCPDP Annual Conference on May 5, 2026, focusing on AI's impact on ePrescribing.
  • Brad Engels, FDB's senior product manager, will lead a session titled 'First Steps of AI's Revolutionary Impact on Prescription Processing'.
  • FDB is highlighting AI-driven solutions like MedProof MCP, Script Agent, and VerifyAssist to automate prescription workflows.
  • The session will explore how AI can improve accuracy, reduce manual steps, and enhance interoperability across prescribing and pharmacy settings, particularly with NCPDP SCRIPT transactions.

The big picture

FDB's focus on AI-driven automation addresses a long-standing pain point in the ePrescribing process – the significant manual effort required by clinicians and pharmacists. This move positions FDB to capitalize on the growing demand for interoperable healthcare solutions and potentially reduce the administrative burden on healthcare providers, a key driver in cost containment efforts. The integration of ambient AI and NLP capabilities represents a significant advancement in automating complex tasks and improving accuracy within the prescription lifecycle.

What we're watching

Adoption Rate
The pace at which pharmacies and prescribers adopt FDB's AI-powered tools will determine the realized impact on workflow efficiency and cost savings, and will be a key indicator of FDB's market penetration.
Regulatory Scrutiny
Increased reliance on AI in prescription processing may draw regulatory attention regarding data privacy, algorithmic bias, and patient safety, potentially impacting FDB's product development and deployment.
Competitive Landscape
How competitors respond to FDB’s AI-native approach to ePrescribing, and whether they develop similar solutions, will shape the long-term competitive dynamics within the medication workflow automation market.
CID: 1940